Physician profile
Nora Kabil
NPI 1861836496
$6,206.91
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.14 · 2020: $568 · 2021: $1,031 · 2022: $3,038 · 2023: $960 · 2024: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,298 · Honoraria: $175 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.28 |
| Honoraria | $175.00 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,186.03 | 2020-2024 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $612.35 | 2019-2024 | Nucala |
| Kaleo, INC. | $429.18 | 2019-2024 | Auvi-Q |
| Genzyme Corporation | $417.70 | 2020-2024 | |
| Amgen INC. | $286.12 | 2021-2024 | Tezspire |
| Aimmune Therapeutics, INC. | $222.81 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $219.75 | 2019-2023 | Dupixent |
| Optinose US, INC. | $179.97 | 2021-2023 | |
| Grifols USA, LLC | $168.90 | 2021-2024 | Prolastin-C Liquid |
| Pfizer INC. | $121.75 | 2021-2023 | |
| Genentech USA, INC. | $120.67 | 2019-2024 | Xolair |
| Alk-Abello, INC | $82.02 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $70.20 | 2021 | |
| Leo Pharma INC. | $41.77 | 2022 | |
| Phadia US INC. | $17.78 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17.00 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Kabil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.